Preliminary safety, antitumour activity and pharmacodynamic results of the Human Intratumoral Immunotherapy (HIT-IT) trial of MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions

Omid Hamid, MD

Translational Research & ImmunoOncology The Angeles Clinic and Research Institute

Omid Hamid1, Matthew D. Hellmann2, Benedito A. Carneiro3, Thomas Marron4, Vivek Subbiah5, Inderjit Mehmi1, Jim Eyles6, Vincent Dubois6, Benjamin Ridgway7, Oday Hamid7, Amaya Gascó Hernández7

1Medical Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA, USA;2Memorial Sloan Kettering Cancer Center, New York, NY, USA;3Lifespan Cancer Institute, Brown University, Providence, RI, USA; 4Icahn School of Medicine at Mount Sinai, New York, NY, USA; 5MD Anderson Cancer Center, Houston, TX, USA; 6R&D Oncology, AstraZeneca, Cambridge, UK; 7R&D Oncology, AstraZeneca, Gaithersburg, MD, USA

Declaration of interests

Omid Hamid, MD

Consulting/Advisory Boards

Aduro, Akeso, Amgen, BeiGene, BioAtla, Bristol Myers Squibb, Roche Genentech, GlaxoSmithKline, Immunocore, Idera, Incyte, Janssen, Merck, NextCure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Tempus, Zelluna

Speakers' Bureaus

Bristol Myers Squibb, Novartis, Pfizer, Sanofi/Regeneron Contracted Research (For Institution)

Arcus, Aduro, Akeso, Amgen, BioAtla, Bristol Myers Squibb, CytomX, Exelixis, Roche Genentech, GlaxoSmithKline, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Torque, Zelluna

MEDI1191 (IL-12 mRNA) promotes antitumour immunity via multiple mechanisms

­ PD-L1 (tumor / leukocytes)


Hewitt SL, et al. Clin Cancer Res. 2020; 26(23):6284-6298

CD, cluster of differentiation; IFNγ, interferon gamma; IL-12, interleukin-12; mRNA, messenger ribonucleic acid; NK, natural killer.

Dosing scheme

MEDI1191 IT dosing

MEDI1191 IT dosing


Part 1B and 1D Concurrent MEDI1191 + durvalumab

BiopsyDay -28

ScreeningDay -28

BiopsyDay 1

Day 22

DLT assessmentMEDI1191 + durvalumabMEDI1191 + durvalumab

Day 43 Disease assessment and biopsy

MEDI1191 + durvalumabDay 71


Day 1

DLT assessment

Day 29

Day 57 Disease assessment and biopsy

DurvalumabDay 99

MEDI1191 + durvalumab

D Q4WD Q4W; MEDI1191 Q8W

Day 85

Day 113

DLT, dose limiting toxicity

This is an excerpt of the original content. To continue reading it, access the original document here.


  • Original document
  • Permalink


Moderna Inc. published this content on 02 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 March 2021 17:35:04 UTC.